

Testing Pneumonia vaccine with a COVID booster

Pfizer begins testing pneumonia vaccine with a COVID booster for seniors all aged 65 years and older. 600 participants will start the trial with Pfizer pneumococcal vaccine following a third dose of the company's approved COVID-19 shot. The participants will be followed for 6 months to assess the safety of co-administering the two vaccines and to take its affect. The FDA pledged in February that it would fast-track approval of booster drugs to strengthen COVID-19 vaccine protection against virus variants.



https://www.mcknights.com/news/clinical-news/pfizer-begins-testing-pneumonia-vaccine-with-a-covid-booster-in-seniors/?utm_source=newsletter&utm_medium=email&utm_campaign=MLT_ClinicalDaily_20210525&hmSubId=&hmEmail=&email_hash=a0b6dbe14475275d054e82048b9b9fad&mpweb=1326-18722-621140